Prognostic and clinicopathological value of BUB1B expression in patients with lung adenocarcinoma: a meta-analysis.

BACKGROUND

Abnormal BUB1B expression has been proven to be related to the poor prognosis of various tumors. This meta-analysis aimed to identify the prognostic role of BUB1B in patients with lung adenocarcinoma (LUAD).

RESEARCH DESIGN AND METHODS

Relevant studies from the PubMed, Embase, Web of Science, and Cochrane Library databases and two public databases that stored sequencing data were retrieved. The standardized mean difference (SMD) and 95% confidence intervals (CIs) for the association between the BUB1B expression level and clinical characteristics were calculated. Pooled hazard ratios (HRs) and 95% CIs were calculated to estimate the association between BUB1B expression and survival outcomes.

RESULTS

A total of 16 studies involving 2771 LUAD patients with BUB1B expression were included in this meta-analysis. Patients with older age showed low BUB1B expression. High BUB1B expression was associated with male sex, a smoking history, and an advanced TNM stage. High BUB1B expression was predictive of poor overall survival (OS) and progression-free survival (PFS). In addition, no publication bias was found.

CONCLUSIONS

This meta-analysis demonstrates that BUB1B is a significant biomarker for a poor prognosis and poor clinicopathological outcomes in patients with LUAD.